EMA Validation of ENHERTU Breast Cancer Treatme...

By HEOR Staff Writer

February 20, 2026

EMA Validates ENHERTU Breast Cancer Treatment Variation The European Medicines Agency (EMA) has validated a Type II Variation marketing authorization application for ENHERTU br...
Glofitamab Cost-Effectiveness: Conditional Reimbursement Insights for DLBCL T...
Advancing Cancer Screening in Slovenia: A Pathway to Equitable Care
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion i...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Re...
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes
Tislelizumab NSCLC Inclusion Recommended for Dutch Health Package
Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthroug...
CHMP January 2026 Approvals: Expanding Access to Innovative Therapies
Latin America Pharma Growth: Boehringer Ingelheim’s Strategic Investmen...
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...